The Additive Effect of Theophylline on a High-Dose Combination of Inhaled Salbutamol and Ipratropium Bromide in Stable COPD

Nishimura, Koichi; Koyama, Hiroshi; Ikeda, Akihiko; Sugiura, Naoharu; Kawakatsu, Kazuo; Izumi, Tohru

doi:10.1378/chest.107.3.718

Cited by 35 publications

(22 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, the interindividual variability of the bronchodilating effect can be high. The efficacy of combining either short or long-acting β 2 -agonists with anticholinergics (COMBIVENT 1994; van Noord et al 2000, 2006), anticholinergics and theophylline (Bleecker and Britt 1991; Bellia et al 2002), and all three classes of bronchodilators is known (Nishimura et al 1995). A fixed inhaled combination of albuterol and ipratropium is available.…”

Section: Treatment Of Stable Chronic Obstructive Pulmonary Diseasementioning

confidence: 99%

Pharmacological treatment of chronic obstructive pulmonary disease

Montuschi

2006

International Journal of COPD

View full text Add to dashboard Cite

None of the drugs currently available for chronic obstructive pulmonary disease (COPD) are able to reduce the progressive decline in lung function which is the hallmark of this disease. Smoking cessation is the only intervention that has proved effective. The current pharmacological treatment of COPD is symptomatic and is mainly based on bronchodilators, such as selective β2-adrenergic agonists (short- and long-acting), anticholinergics, theophylline, or a combination of these drugs. Glucocorticoids are not generally recommended for patients with stable mild to moderate COPD due to their lack of efficacy, side effects, and high costs. However, glucocorticoids are recommended for severe COPD and frequent exacerbations of COPD. New pharmacological strategies for COPD need to be developed because the current treatment is inadequate.

show abstract

Section: Treatment Of Stable Chronic Obstructive Pulmonary Diseasementioning

confidence: 99%

Pharmacological treatment of chronic obstructive pulmonary disease

Montuschi

2006

International Journal of COPD

View full text Add to dashboard Cite

show abstract

“…Adding theophylline, leukotriene antagonists or antihistamines in routine treatment protocol seem to ameliorate respiratory symptoms [21], improve PFT, dyspnea score and QOL in stable COPD [22], accordingly these agents were utilized wherever necessary. Oral tablets/capsules were preferred dosage form; however, it is highly recommended that physicians prescribe inhalers more than tablets/ capsules.…”

Section: Discussionmentioning

confidence: 99%

EMPADE Study: Evaluation of Medical Prescriptions and Adverse Drug Events in COPD Patients Admitted to Intensive Care Unit

Adil

Khan

et al. 2015

JCDR

View full text Add to dashboard Cite

Inclusion/ exclusion criteriaPatients elder than 18 years of both genders suffering from COPD and willing to give consent were included, whereas pregnant women and pediatric patients were excluded from the study. StAtIStIcAl AnAlySISData comprising patient demographics, co-morbidities, medications prescribed and daily progress of patient were collected from treatment charts/case sheets, laboratory reports and verbal information

show abstract

“…It is difficult to compare the effect on COPD exacerbations since this end point was not commonly assessed during most theophylline studies. Two early theophylline studies reported no effect on COPD exacerbations [70,71]. A subsequent 1-year trial of low-dose theophylline compared with placebo did show an increase in time to the first COPD exacerbation, reduced frequency of COPD exacerbations (0.79+1.16 versus 1.70+2.61, p = 0.047) and greater improvement in SGRQ (-27.63+19.73 versus -19.80+22.88, p = 0.047) [72].…”

Section: Inhaledmentioning

confidence: 99%

Phosphodiesterase 4 inhibitors for the treatment of chronic obstructive pulmonary disease: a review of current and developing drugs

Mulhall

Droege

Ernst

et al. 2015

Expert Opinion on Investigational Drugs

View full text Add to dashboard Cite

After decades of research in drug development, PDE4Is are a welcomed addition to the COPD therapeutic armamentarium. In its current clinical role, the salubrious clinical effects of PDE4I in reducing exacerbations and stabilizing the frequent exacerbator phenotype have to be cautiously balanced with numerous adverse effects. Developing drugs may provide similar or better clinical benefits while minimizing adverse effects by changing the mode of drug delivery to inhaled formulations, combining dual PDE isoenzyme inhibitors (PDE1/4I and PDE3/4I) and by forming hybrid molecules with other bronchodilators (muscarinic receptor antagonist/PDE4I and β2-agonist/PDE4I).

show abstract

The Additive Effect of Theophylline on a High-Dose Combination of Inhaled Salbutamol and Ipratropium Bromide in Stable COPD

Cited by 35 publications

References 35 publications

Pharmacological treatment of chronic obstructive pulmonary disease

Pharmacological treatment of chronic obstructive pulmonary disease

EMPADE Study: Evaluation of Medical Prescriptions and Adverse Drug Events in COPD Patients Admitted to Intensive Care Unit

Phosphodiesterase 4 inhibitors for the treatment of chronic obstructive pulmonary disease: a review of current and developing drugs

Contact Info

Product

Resources

About